THE US Food and Drug
Administration is considering
approving an implant designed to
reduce addict’s cravings for heroin
or painkillers.
The implant which is used for six months
provides a steady dosage of
buprenorphine and naloxone, drugs
shown to ease withdrawals and
decrease cravings.
The drug combination
was developed by Braeburn
Pharmaceuticals.
In a six-month clinical trial of the
implant last Jun, 88% of the 178
participants ceased their addiction.
The FDA is expected to announce
its decision on 27 Feb.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jan 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.